To include your compound in the COVID-19 Resource Center, submit it here.

Xtandi enzalutamide regulatory update

Medivation and Astellas said EMA’s CHMP recommended approval of a Type II variation for Xtandi enzalutamide to

Read the full 175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE